| abstract |
The invention relates to a fixed-dose, immediate-release dosage form containing ezetimibe and a pharmaceutically acceptable salt of rosuvastatin, in which each of the active ingredients is individually encapsulated in tablets, and the release of the active ingredient from said tablets is time-divided so that the disintegration time difference tablets containing the pharmaceutical salt of rosuvastatin and ezetimibe, is from 5 to 1800 s; moreover, the tablet containing ezetimibe contains sodium lauryl sulfate, and the tablet containing a pharmaceutically acceptable salt of rosuvastatin, contains from 5 to 40 wt.% salt of rosuvastatin, from 60 to 95 wt.% microcrystalline cellulose, from 0.05 to 2.0 wt. % colloidal silicon dioxide and from 0.1 to 2.0 wt.% a lubricant; and a pharmaceutically acceptable salt of rosuvastatin is selected from a salt of rosuvastatin zinc (2: 1). The invention improves the dissolution rate of ezetimibe. |